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From 2000 to 2004, 36, 58, 72, 78, and 86 laboratories participated
in an external quality assessment scheme (EQAS) organized by the
Department of Transfusion Medicine, Faculty of Medicine Siriraj
Hospital. Each year the staff was requested to perform ABO
grouping, D typing, antibody screening, antibody identification, and
DATs on eight blood samples. Each participant received
information on the correct test results and a coded summary.
Regarding ABO grouping, the error rate ranged from 0.3 to 1.3
percent,mostly due to human errors. Error rates in D typing ranged
from 0.7 to 5.7 percent, the most problematic being weak D
phenotype interpretation. Although every sample was negative by
the DAT, error rates due to false positive test results were
determined to be 0.4 to 2.1 percent. Antibody screening errors
were also found; however, errors steadily decreased from 4.2
percent in 2000 to 0.3 percent in 2004. Only 69.4 to 87.2 percent
of laboratories performed antibody identification; however, correct
results increased from 78.4 to 91.0 percent. In conclusion,an EQAS
in RBC serology should be used to compare results from different
laboratories and to identify those laboratories that need
improvement in testing procedures. Immunohematology
2006;22:1–5.
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Quality assurance in transfusion medicine includes
the use of and participation in internal and external
quality programs. Quality management is essential to
ensure that laboratory performance is reliable and
accurate on a daily basis. However, an external quality
assessment scheme (EQAS) that compares results from
different laboratories is essential to verify the accuracy
and reliability of laboratory results.1–5 This study was
undertaken to evaluate RBC serology testing services
among hospital blood banks in Thailand.
Among Thai hospital laboratories, the quality
assurance program for blood transfusion services was
established in 1988. From 1994 to 1997, the Bureau of
Laboratory Quality Standards, Department of Medical
Sciences,Ministry of Public Health, in cooperation with
the Subcommittee on Transfusion Medicine, set up the
first proficiency test on RBC serology for hospital
blood banks throughout the country. The proficiency
testing samples obtained from the National Blood
Centre, Thai Red Cross Society, were sent to every
member three times per year without charge. At first,
all members were requested to perform only ABO
grouping and antibody screening tests. Eleven serum
samples were sent to 127 blood banks, revealing an
overall accuracy of 94.15 percent.6 Beginning in 2002,
D typing and antibody identification tests were also
performed. The results of the tests performed were
evaluated using target values. Additionally, from
November 1996 to August 1997, 20 blood banks in
Bangkok were asked to participate in an external
quality control study in immunohematology that was
organized by the Department of Transfusion Medicine,
Faculty of Medicine Siriraj Hospital,Mahidol University.
Each blood bank was requested to perform ABO and D
typing, antibody screening, antibody identification, and
direct antiglobulin tests (DAT) on eight blood samples.
Surprisingly, only three public hospital blood banks
reported correct results for all tests on every blood
sample.
The second external quality assessment program
from the Department of Transfusion Medicine, Faculty
of Medicine Siriraj Hospital, Mahidol University, started
in 2000. In the beginning, 36 laboratories joined the
program,with only 13.9 percent of them reporting 100
percent correct results for tests on eight blood
samples.7 Over time, more blood banks joined the
program. The number of blood banks participating was
58, 72, 78, and 86 in 2001, 2002, 2003, and 2004,
respectively. At the end of each year, our laboratory
prepared a list of the errors made by each blood bank
and the results were discussed at our annual meeting.
The purpose of the 2000 to 2004 EQAS was to
evaluate the efficiency of the blood bank staff who
perform routine laboratory tests, such as compatibility
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testing,antibody screening,and antibody identification.
Analysis of the study results could help blood banks
consider more appropriate policies for increasing staff
efficiency, performance, and accuracy.
Materials and Methods
Blood samples
For each year in the study (2000 to 2004), eight
blood samples were distributed to participating blood
banks. The Department of Transfusion Medicine
prepared four blood samples and four were prepared
by DiaMed AG, Switzerland. Samples were distributed
four times per year. Each time, two unknown samples,
consisting of 5 ml serum and 5 ml RBC suspension in
Alsever’s solution, were shipped to participants,
packed in wet ice. The samples were distributed by the
supplier and each participant received them within 3
days. The participants were instructed to handle these
samples as part of their routine work, to have these
tests performed by a technician on duty within 3 days
after receipt, and to return the results by surface mail
or fax within 2 weeks. Late results were not included
in the analysis.
Tests performed
Each hospital blood bank was requested to perform
five tests using their routine reagents and methods, such
as the conventional tube technique or gel test. These
tests included ABO grouping, D typing, antibody
screening and identification, and a DAT. A result form
was developed and used to record the individual
hospital test results and the testing method used. The
results from all blood banks were compiled and assessed
and the correct test results, the individual laboratory
performance, and a coded summary of the results of all
participants were shared with all participants. This
enabled them to have interlaboratory comparison.
Additionally, at the end of the year, a summary of each
laboratory’s performance was reported to the head of
the blood bank laboratory and hospital director for each
facility. This allowed them to be aware of capacity
building needed for laboratory personnel as well as
equipment, reagents, and methods used.
Moreover, to educate and increase the awareness of
all members, a workshop was set up at the end of each
year. Every participant was invited free of charge and a
lecture on relevant topics was given. Causes of
discrepant results, challenges, and any difficulties
occurring during the program were discussed and
resolved with an organizing team.
Results
Details of the samples with or without antibody
identification distributed in 2000 to 2004 are
summarized in Table 1. The number of blood bank
laboratories participating in the EQAS on RBC serology
from 2000 to 2004 was 36, 58, 72, 78, and 86 for each
year, respectively (Table 2). Causes of errors in ABO
grouping, D typing, DAT, and antibody screening tests
are summarized in Table 3. For ABO grouping, all
participants performed both RBC and serum grouping
but some errors in reporting still occurred. The error
rates for the 5 years were 0.7, 1.3, 0.9, 0.6, and 0.3
percent, respectively (Table 2). Errors in ABO grouping
tests were classified as human, misinterpretation, and
technical. Human errors included those that occurred
because of failure to interpret or record correct test
results, inadequate identification of blood specimens
such as testing old EQAS samples instead of the current
ones, and sample mixups. Errors classified as
misinterpretation included those that occurred
because of the inability to interpret results because of
ABO discrepancies caused by antibodies that went
undetected because antibody identification was not
performed. Technical errors included those that
occurred because of the failure to detect antibodies of
the ABO system; positive results were missed.
Regarding D typing, error rates were 0.7, 5.7, 2.3, 4.8,
and 3.2 percent, respectively (Table 2). The high error
rates in the year 2001 and 2003 were due to variation
in the reporting of RBC samples with a weak D
phenotype as either D– or D+ (Table 3). These errors
were classified as those caused by misinterpretation.
Again, human errors in this category were caused by a
mixup of specimens. Errors classified as reagent errors
occurred because some commercial reagents gave
strong positive results in the immediate spin phase
while others gave negative results. Technical errors
included those caused by D– RBCs that were
interpreted as D+ or as a weak D phenotype.
Negative DAT results were correctly ascertained;
however, error rates due to false positive test results
were found to be 2.1, 1.1, 0.4, 1.6, and 1.2 percent,
respectively (Table 2). The misinterpretation error that
occurred in one laboratory was caused by a mixup
between DAT and antibody screening tests results
(Table 3). They reported positive DAT results instead of
antibody screening results. Errors caused by improper
testing procedures that resulted in the reporting of
DAT negative samples as DAT positive were classified
as technical.
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Errors in antibody screening were also found.
Errors rates were 4.2, 1.1, 1.4, 0.8, and 0.3 percent,
respectively (Table 2). Errors caused by reagents
occurred because inappropriate locally made
screening RBCs, which lacked some antigens such as
Mia, E, K, P1, or M, were used. Therefore, such
antibodies could not be detected. Technical errors
again included those caused by improper testing
techniques that resulted in the reporting of negative
antibody screening test results as positive. On the
contrary, some positive antibody screening test results
were reported as negative even though their screening
RBCs contained the specific antigens.
Antibody identification was not routinely
performed in all blood bank laboratories participating
from 2000 to 2004. In the first year, only 25 out of 36
laboratories (69.4%) performed this procedure.
Routinely, the other blood bank laboratories, which did
not perform antibody identification, sent the blood
samples with positive antibody screening results to the
National Blood Centre of the Thai Red Cross Society for
investigation and crossmatching. Because of the
explanations and recommendations given at the
workshop, the number of participating laboratories
performing antibody identification increased from 79.3
to 87.2 percent.
The results of antibody identification testing were
the most striking. In 2000, among 36 participants, only
78.4 percent reported correct results for all eight blood
samples. The correct results increased to 79.1 percent
in 2001, 90.7 percent in 2002, 91.0 percent in 2003,
and 91.0 percent in 2004, as shown in Table 2.
Moreover, due to the workshop discussions on how to
decrease errors, the number of participants reporting
correct results for all tests on the eight blood samples
each year gradually increased: 5 of 36 (13.9%) in 2000,
8 of 58 (13.8%) in 2001,29 of 72 (40.3%) in 2002, 21 of
78 (26.9%) in 2003, and 37 of 86 (43.0%) in 2004.
Every blood bank laboratory sent one or two
members of its staff to attend the end-of-year workshop
and each received a certificate of attendance. In
addition, an award was given to the blood bank
laboratories that reported all results correctly.
Discussion
External proficiency testing programs offer a
valuable management tool because they enable
laboratory personnel to compare their laboratory
results with those obtained in other laboratories when
the same material is examined. The proficiency testing
samples must be tested with the laboratory’s regular
patient workload, using routine testing methods. In
this study, the organizing team also reported the
laboratory performance to the chief of laboratories as
well as hospital directors. Therefore, these EQAS help
evaluate the performance of procedures, equipment,
materials, and personnel of the individual blood bank
or transfusion service and suggest areas for
improvement.1–5
The results of this study indicated that only 13.9 to
43.0 percent of the participating hospitals reported
100 percent correct results for all tests on eight blood
samples in each year, which is similar to previous
studies’ results.7 ABO grouping errors occurred
because of human error in the interpretation of results.
Table 1. Distribution of proficiency testing samples from 2000 to 2004*
Number of samples
2000 2001 2002 2003 2004
ABO grouping
A (12) 2 3 2 3 2
B (9) 1 2 3 1 2
AB (2) 1 0 0 0 1
O (17) 4 3 3 4 3
D typing
D+ (21) 5 5 4 3 4
D– (12) 2 1 3 3 3
Weak D phenotype (7) 1 2 1 2 1
DAT
Positive (0) 0 0 0 0 0
Negative (40) 8 8 8 8 8
Antibody screening
Positive (33) 7 5 8 7 6




anti-E (2) 1 0 1 0 0
anti-P1 (3) 0 1 1 1 0
anti-Mia (2) 1 0 1 0 0
anti-M (1) 0 0 0 0 1
anti-D (1) 0 0 0 0 1
Import (DiaMed)
anti-D (1) 0 0 1 0 0
anti-c (3) 0 1 1 0 1
anti-e (2) 1 0 0 1 0
anti-K (3) 1 0 1 1 0
anti-E (2) 0 0 0 1 1
Mixture of antibodies (13)
Inhouse (Siriraj)
anti-D, -Mia (1) 0 0 0 1 0
anti-D, -C (1) 1 0 0 0 0
anti-D, -E (1) 0 0 1 0 0
anti-E, -Mia (3) 0 1 0 1 1
anti-P1, -Mia (1) 0 1 0 0 0
Import (DiaMed)
anti-D, -Fya (1) 0 1 0 0 0
anti-c, -K (2) 1 0 1 0 0
anti-C, -D, -E (1) 1 0 0 0 0
anti-D, -E (1) 0 0 0 1 0
anti-D, -K (1) 0 0 0 0 1
*Number in parentheses is total number of samples from 2000 to 2004.
If a patient receives mistyped blood, especially an ABO
mismatch, this can result in a life-threatening event.
RBC samples that were D– as well as those of the weak
D phenotype were also mistyped because of technical
errors and result misinterpretation. Moreover, some
commercial monoclonal anti-D reagents gave strong
agglutination with RBCs of the weak D phenotype.
This should be noted because patients with an
apparent weak D phenotype who may have a partial D
phenotype may be considered D+ and if D+ RBCs are
given, anti-D could be made. On the other hand, donor
RBCs of the weak D phenotype must be identified as
such. RBC products from these donors should be
labeled as D+ and given to D+ patients in order to
prevent the production of anti-D.8 Even though some
reduction in the number of ABO and D typing test
result errors were found, the error rates were still
higher than those found in the previous studies in the
United Kingdom.9–10
The false positive results in the DAT should lead
some blood banks to reevaluate their reagents and
testing procedures. Because anti-E is one of the
common Rh antibodies and anti-K is uncommon
among the Thai population, the use of locally made
screening RBCs, which lack these antigens, might
explain the errors in antibody screening tests and why
these antibodies were not identified.11–14 When the
appropriate screening RBCs, which included all
clinically significant antigens, and methods, such as
saline IAT,enzyme,and LISS IAT,were used, these blood
bank laboratories could identify antibodies in other
samples containing a mixture of antibodies such as
anti-c, -K and anti-E, -Mia.
Moreover, for antibody identification of two or
three antibodies, such as anti-c, -K, anti-C, -D, and anti-C,
-D, -E, only 40 to 80 percent of the hospitals could
report the correct antibody specificity. When
appropriate panel RBCs and second panel RBCs
together with different methods were used, the
hospitals could identify these antibody specificities. In
Thailand, in addition to inhouse screening and panel
RBCs, laboratories can obtain these from the National
Blood Centre at a reasonable price. The study showed
that errors in antibody identification could not be
attributed to the reagents and the reason some
laboratories did not perform this test may be due to the
policy of those laboratories. However, to differentiate
whether there is another antibody in the serum sample
or not, extra RBCs of known rare phenotypes are
needed. In addition, antigen typing of the patient’s
RBCs should be performed before reaching any
conclusion. Moreover, staff who are experienced with
appropriate testing procedures are needed to identify
more complex samples.3,4
Our results showed the same pattern as that of the
National External Quality Assessment Scheme in Blood
Group Serology, organized by the Bureau of Laboratory
Quality Standards, which sent unknown samples to
various blood banks in the country (622 in 2002 and
653 in 2003). They found that among 285 blood banks
(51%) who continuously reported test results, 5
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Table 2. Summary of ABO, D, DAT, antibody screening, and antibody identification test results (2000–2004)
Antibody Antibody 
Year N ABO D DAT screening identification
✔ ✘ ✔ ✘ ✔ ✘ ✔ ✘ ✔ ✘
2000 36 93.3 0.7 99.3 0.7 97.9 2.1 95.8 4.2 78.4 21.6
2001 58 98.7 1.3 94.3 5.7 98.9 1.1 98.9 1.1 79.1 20.9
2002 72 99.1 0.9 97.7 2.3 99.6 0.4 98.6 1.4 90.7 9.2
2003 78 99.4 0.6 95.2 4.8 98.4 1.6 99.2 0.8 91.0 9.0
2004 86 99.7 0.3 96.8 3.2 98.8 1.2 99.7 0.3 91.0 9.0
N = number of blood bank laboratories          ✔ = correct results (%)          ✘ = wrong results (%)
Table 3. Summary of the nature of the errors in ABO grouping, D typing,
DAT, and antibody screening tests (2000–2004)
Number of blood banks reporting
incorrect results
2000 2001 2002 2003 2004
ABO grouping
Human errors 2 4 1 2 1
Misrepresentation 0 1 2 1 0
Technical errors 0 0 0 0 0
D typing
Human errors 0 2 0 1 0
Misrepresentation 0 8 4 14 1
Reagents 0 9 2 3 1
Technical errors 2 3 6 7 20
DAT
Misrepresentation 1 0 0 0 0
Technical errors 4 4 1 7 5
Antibody screening
Reagents (screening RBCs) 4 0 5 3 2
Technical errors 7 3 2 1 1
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percent (15 of 285) and 0.3 percent (1 of 254) had
unacceptable results for ABO and D typing tests,
respectively. In addition, of the 57.2 percent (163 of
285) and 16.8 percent (48 of 285) of blood banks that
reported the results of antibody screening and
antibody identification tests, 27 percent (44 of 163)
and 73 percent (35 of 48) had excellent results.15
In conclusion, internal and external quality
assessment programs should be maintained in order to
ensure effective transfusion service and safety of
patients. In addition to hospital accreditation, the
hospital administration should support training and
continuing education to improve the ability of the
blood bank staff to perform all tests and evaluate their
results.
Acknowledgments
We would like to thank all blood banks that
participated in our EQAS.
References
1. Bert LM. Quality in Blood Banking. In: Harmening
DM, ed. Modern blood banking and transfusion
practices. 4th ed. Philadelphia: F.A. Davis
Company, 1999:326-42.
2. Petz LD, Swisher SW. Transfusion medicine in a
hospital setting. In: Petz LD, Swisher SN, Kleinman
S, Spence RK, Strauss RG, eds. Clinical practice of
transfusion medicine. 3rd ed. New York: Churchill
Livingstone, 1996:335-47.
3. Menitove JE. Process control. In: Standard for
blood banks and transfusion services. 22nd ed.
Bethesda: American Association of Blood Banks,
2003:11-69.
4. Menitove JE. Assessments: internal and external.
In: Standard for blood banks and transfusion
services. 22nd ed. Bethesda:American Association
of Blood Banks, 2003:93.
5. Brecher ME. Quality issues. In: Technical manual.
14th ed. Bethesda: American Association of Blood
Banks, 2002:1-88.
6. Petchoopong A and Thaworn C. The proficiency
test in antibody screening test of blood bank
laboratories in different level hospitals 1994-1997.
Thai J Hematol Transfus Med 1999; 9:185-93.
7. Bejrachandra S, Nathalang O, Saipin J, et al.
External quality control program in red cell
serology. In:Kanno T,Okabe H,Tatsumi N,Mori M,
Ichiyama S, eds. Global standardization and
advanced quality management ‘01. Quality control
in the clinical laboratory. Osaka: Eibun Press,
2002:194-6.
8. Brecher ME.The Rh system. In:Technical manual.
14th ed. Bethesda: American Association of Blood
Banks, 2002:295-313.
9. Holburn AM, Prior DM. The UK national external
quality assessment scheme in blood group
serology. ABO and D grouping and antibody
screening 1982-1983. Clin Lab Haematol
1986;8:243-56.
10. Holburn AM, Prior DM, Whitton CM. The UK
national external quality assessment scheme in
blood group serology. ABO and D grouping and
antibody screening, direct antiglobulin test and
antibody identification 1984-1985. Clin Lab
Haematol 1988;10:73-85.
11. Chandanayingyong D. Common problems in
routine pre-transfusion testing. Southeast Asian J
Trop Med Public Health 1979;10:193-5.
12. Bejrachandra S,Chandanayingyong D.Unexpected
red cell antibodies in donors and patients at Siriraj
Hospital. Southeast Asian J Trop Med Public
Health 1979;10:204-6.
13. Nathalang O, Kuvanont S, Punyaprasidth P,
Tasaneeyanond C, Sriphaisal T.A preliminary study
of the distribution of blood group systems in Thai
blood donors determined by the gel test.
Southeast Asian J Trop Med Public Health
2001;32:419-24.
14. Bejrachandra S, Nathalang O, Saipin J, et al.
Distribution of blood group systems in Thai blood
donors determined by the gel test. Siriraj Hosp
Gaz 2002;54:403-9.
15. Soisangwan R. National external quality
assessment scheme in blood group serology in
Thailand, 2002-2003 experience. Thai J Hematol
Transf Med 2004;14:7-21.
Sasitorn Bejrachandra, MD, and Jariya Saipin, MSc,
Department of Transfusion Medicine, Faculty of
Medicine Siriraj Hospital, Mahidol University,
Bangkok 10700, Thailand; Oytip Nathalang, PhD,
Phramongkutklao College of Medicine, Bangkok,
Thailand; Usanee Siriboonrit, MSc, Ekaraj
Rungroung, MSc, and Sudjai Udee, BE, Faculty of
Medicine Siriraj Hospital, Mahidol University,
Bangkok, Thailand.
